IBIO Share Price

Open 0.41 Change Price %
High 0.42 1 Day 0.00 0.00
Low 0.39 1 Week 0.00 0.00
Close 0.40 1 Month -0.02 -4.76
Volume 100396 1 Year -0.24 -37.50
52 Week High 0.80
52 Week Low 0.33
IBIO Important Levels
Resistance 2 0.43
Resistance 1 0.42
Pivot 0.40
Support 1 0.38
Support 2 0.37
AMEX USA Most Active Stocks
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
RBY 0.03 -70.00%
NGD 3.03 -3.81%
NGD 3.03 -3.81%
CVM 0.11 10.00%
CVM 0.11 10.00%
NG 4.05 -5.37%
NG 4.05 -5.37%
More..
AMEX USA Top Gainers Stocks
GGR 0.02 100.00%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
MBA 0.20 25.00%
MBA 0.20 25.00%
MBA 0.20 25.00%
IG 7.68 22.49%
IG 7.68 22.49%
More..
AMEX USA Top Losers Stocks
CHGS 0.00 -100.00%
RBY 0.03 -70.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
QBC 0.20 -33.33%
CMFO 0.04 -33.33%
ATL 0.06 -25.00%
ATL 0.06 -25.00%
SNT 0.12 -20.00%
More..

iBio, Inc. (AMEX: IBIO)

IBIO Technical Analysis 5
As on 25th Apr 2017 IBIO Share Price closed @ 0.40 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.52 & Strong Sell for SHORT-TERM with Stoploss of 0.42 we also expect STOCK to react on Following IMPORTANT LEVELS.
IBIO Target for April
1st Target up-side 0.53
2nd Target up-side 0.6
3rd Target up-side 0.67
1st Target down-side 0.33
2nd Target down-side 0.26
3rd Target down-side 0.19
IBIO Other Details
Segment EQ
Market Capital 43945728.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.ibioinc.com
IBIO Address
IBIO
9 Innovation Way
Suite 100
Newark, DE 19711
United States
Phone: 302-355-0650
Interactive Technical Analysis Chart iBio, Inc. ( IBIO AMEX USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on iBio, Inc.
IBIO Business Profile
iBio, Inc., a biotechnology company, focuses on the commercialization of its proprietary plant-based protein expression technologies in the United States and internationally. Its proprietary technologies include iBioLaunch, a transformative platform technology for the development and production of biologics; and iBioModulator, a technology platform that improves the potency and duration of the effect of prophylactic and therapeutic vaccines. The company’s product candidates include C1 Esterase Inhibitor, a preclinical stage plasma-derived protein; Alpha-Galactosidase, a preclinical orphan designation stage enzyme replacement; and Palivizumab, a preclinical stage monoclonal antibody for the therapeutic protein market. Its product candidates also comprise H1N1 Influenza and H5N1 Influenza viral disease vaccines that completed Phase I; Hookworm parasitic pathogen vaccine, which is in preclinical stage; and Human Papillomavirus therapeutic vaccine that is in preclinical stage. In addition, the company’s product candidates include Anthrax/Plague bacterial disease vaccine that is in preclinical stage; and Anthrax monoclonal antibody that is in preclinical stage for the Biodefense market. It has a collaboration agreement with Fraunhofer Center for Molecular Biology to perform research and development activities to develop the recombinant form of C1 esterase inhibitor; an alliance with GE Healthcare to commercialize its plant-based technologies for the manufacture of biopharmaceuticals and vaccines; a collaboration agreement granting FioCruz/Bio-Manguinhos a license to use its proprietary technology in connection with the development, manufacture, and commercialization of vaccine products; and a license and collaboration agreement enabling Caliber Biotherapeutics LLC to use its iBioLaunch platform in connection with the development of an undisclosed monoclonal antibody-based therapeutic protein for an oncology indication. The company is headquartered in Newark, Delaware.